atugen AG, a private company focused on the elucidation of disease pathways, today announced the identification of a novel cancer target that appears to play an important role in tumor growth and metastasis. atugen’s research group has demonstrated that inhibition of the novel target, Atu027, which has homology to protein kinases, results in blockage of tumor growth of human prostate carcinoma cells in orthotopic mouse models. atugen has demonstrated that human prostate tumor cells engineered to express siRNA molecules against the kinase shows significant reduction or even complete lack of secondary tumors indicating a role of the kinase in tumor progression and metastasis.
The novel target, Atu027, is the result of the companys internal research program on the phosphatidylinositol 3-OH kinase (PI 3-K) pathway. The approach was presented at the Cold Spring Harbor Laboratory’s Tumor Suppressor August 2002 Meeting in Cold Spring Harbor, NY. PI 3-K is a central signal transduction molecule controlling a wide range of cellular responses including contributing to increased malignant behavior of cancer cells.
The identification and functional validation of the kinase as PI 3-K downstream effector molecule underscores the strength of the atugen approach to find novel targets. The use of the company’s proprietary mRNA knockdown technologies (GeneBlocs® antisense molecules, improved synthetic siRNA, vector expression systems for siRNA, ribozymes and superior transfection reagents) together with atugen’s expertise in gene function elucidation has to date resulted in 19 functionally validated cancer targets that act in the PI 3-K pathway.
Caroline Stupnicka | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News